Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05000931
Other study ID # CAM 5766
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 26, 2022
Est. completion date March 14, 2024

Study information

Verified date April 2024
Source Cochlear
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD).Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Thus the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.


Description:

The CochlearTM Osia®2 System was cleared by the Food and Drug Administration November 15, 2019 (K191921) for individuals aged 12 years and older who present with conductive or mixed hearing loss (up to 55 dB HL) or single-sided-deafness (SSD). Published and unpublished data suggest significant pre to postoperative benefit and minimal risk in both children and adults who have received the Osia system. Due to the success of the Osia 2 system in the United States within the currently indicated patient population, clinical providers have since requested the ability to use the Osia 2 system in children aged 11 years and younger who meet the audiometric requirements. As the Osia 2 system is based on existing bone conduction and cochlear implant technologies which each possess a younger age of implantation requirement (5 years for bone conduction and 9 months for cochlear implantation), the current proposal is to align the age at implantation requirement with existing surgical bone conduction technology such as the Baha Connect and Baha Attract Systems to 5 years of age. Therefore, the objective of this study is to examine the safety and effectiveness of the Cochlear Osia 2 system in a group of pediatric subjects aged 5 to 11 years who suffer from conductive or mixed hearing loss (up to 55 dB HL), or single-sided-deafness (SSD) with the intent of expanding the indications for use.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 14, 2024
Est. primary completion date September 22, 2023
Accepts healthy volunteers No
Gender All
Age group 5 Years to 11 Years
Eligibility Inclusion Criteria: 1. Subjects aged 5 to 11 years of age with the following audiometric criterion: - A conductive or mixed hearing loss and still can benefit from sound amplification. The pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2, and 3 kHz) should be better than or equal to 55 dB HL. OR - A profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e., single-sided deafness or "SSD"). The pure tone average air conduction hearing thresholds of the hearing ear should be better than or equal to 20 dB HL (measured at 0.5, 1, 2, and 3 kHz). 2. Prior experience with amplified sound through properly fitted amplification device such as a hearing aid, a CROS device, or a bone conduction device on a softband or sound arc. 3. Parent or legal guardian who is willing and able to provide written informed consent for the study participant. Note: Subjects may include individuals seeking new implantation unilaterally (in one ear) or individuals already implanted with a bone-anchored device seeking a second-side implant (sequential bilateral) Exclusion Criteria: 1. Insufficient bone quality or quantity to support implantation of both the BI300 Implant and the OSI200 Implant. 2. Chronic or non-revisable vestibular or balance disorders that could prevent benefit from the device, as determined by the investigator. 3. Abnormally progressive hearing loss. 4. Evidence that hearing loss is bilateral retro cochlear or bilateral central origin. 5. Evidence of conditions that would prevent speech recognition improvement as determined by the investigator. 6. Skin or scalp conditions that may preclude attachment of the Sound Processor or that may interfere with the use of the Sound Processor. 7. Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator. 8. Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling. 9. Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this investigation. 10. Currently participating, or participated within the last 30 days, in another clinical investigation involving an investigational drug or device that could impact the safety or effectiveness of the Osia 2 system as determined by the investigator. 11. Individuals undergoing simultaneous single-stage aural atresia or microtia repair due to the increased risk of skin complications associated with ear reconstruction.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Osia 2 System
Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.

Locations

Country Name City State
United States University Hospitals Cleveland Medical Center Cleveland Ohio
United States Texas Children's Hospital Houston Texas
United States Children's Minnesota Minneapolis Minnesota
United States Stanford University Palo Alto California
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Barrow Neurological Institute Phoenix Arizona
United States Rady Children's Hospital San Diego California

Sponsors (3)

Lead Sponsor Collaborator
Cochlear Analytical Solutions Group, Inc., R. P. Chiacchierini Consulting, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Adverse Events Quantified by Type and Severity Between Implantation and 6-months Post-surgery. Adverse events were reported from the time of implantation through 6-months. From implantation to 6 months post-surgery
Secondary Change From Baseline to 6-months Post-surgery in SSQ (Speech, Spatial and Qualities of Hearing Scale) Parent Questionnaire Measuring change of speech, spatial, quality and conversational uses of hearing (27 items in 4 sections). Each item is scored by the parent on a scale of 0 to 10 where 0 corresponds to "not at all" and 10 to "perfectly" when rating their child's ability to hear and listen in everyday situations. The score of a participant is determined as the mean of the scores for the 4 different sections. Higher scores indicate less hearing disability. Baseline before surgery, 6 months post-surgery
Secondary Change From Baseline to 4-weeks Post-surgery in Unaided Bone Conduction Thresholds. The Pure Tone Average (PTA) is calculated as an average of the bone conduction thresholds collected at 500, 1000, 2000, and 4000 Hz. This measure was collected unaided both pre- and post-operatively to ensure no shift in bone conduction hearing as a result of the surgery. Baseline before surgery, 4 weeks post-surgery
Secondary Change in Word Recognition Using Consonant Nucleus Consonant (CNC) Words Presented in Quiet From Unaided Baseline to Aided 6-months Post-surgery. The CNC Words test consists of 10 recorded lists of 50 monosyllabic words. For this study, one list is administered per test condition at 60 dBA in sound field and scored as the number of phonemes and words correct, which will be expressed as a percentage correct when analyzed. The CNC word test has a score range of 0-100% with higher values indicating better scores. Baseline before surgery, 6 months post-surgery
Secondary Change in Sentence Recognition in Noise Using the Bramford Kowal Bench Speech-In-Noise (BKB-SIN) From Unaided Baseline to Aided 6-months Post-surgery. The Bamford-Kowal-Bench Sentence in Noise test (BKB-SIN) consists of 36 paired lists. List of sentences are presented at 65 dBA with the level of noise varied stepwise at fixed signal to noise ratio to obtain a Speech Reception Threshold (SRT) where participants are able to repeat key words 50% of the time. Score range is not specified as metric is adaptive; lower scores indicate better performance. Baseline before surgery, 6 months post-surgery
See also
  Status Clinical Trial Phase
Completed NCT03723161 - Evaluation of the Ponto Bone Anchored Hearing System in a Pediatric Atresia Population
Completed NCT04320407 - Osia CPT Code Study N/A
Active, not recruiting NCT01445977 - SoundBite Hearing System Long Term Multi Site Patient Use Study N/A
Completed NCT02304692 - Clinical Survey of Different Abutment Topologies N/A
Recruiting NCT00393159 - The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children Phase 4
Recruiting NCT06164184 - Interest of the Cone Beam Scanner of Temporal Bones in the Analysis of Conductive Hearing Loss
Not yet recruiting NCT01967498 - Montelukast for Children With Chronic Otitis Media With Effusion (COME): A Double-blind, Placebo-controlled Study N/A
Active, not recruiting NCT05628285 - Evaluation of a Hearing Device for Transmitting Sound to the Inner Ear N/A
Completed NCT03374787 - Evaluation of Sound Processor for a Transcutaneous System N/A
Completed NCT02092610 - Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System N/A
Completed NCT01671176 - Wide Diameter Bone Anchored Implant Study N/A
Completed NCT03086135 - Clinical Performance of a New Implant System for Bone Conduction Hearing N/A
Recruiting NCT01807559 - SoundBite Hearing System 24 Month Multi Site Patient Use Study N/A
Withdrawn NCT01264510 - Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) Phase 4
Recruiting NCT04803279 - Investigating Hearing With Ponto 3 SuperPower, a Bone Anchored Hearing Aid - Investigating Hear
Completed NCT03143257 - Ambispective Clinical Evaluation of Sophono™
Completed NCT02274129 - Clinical Survey of Oticon Medical Healing Cap N/A
Withdrawn NCT03541967 - Comparison of a New Bone Conduction Hearing System to a Osteo-integrated Bone Conduction Hearing Aid on a Softband N/A
Recruiting NCT03327194 - Use of ADHEAR, a Non-Implantable Bone Conduction Hearing System, in Children With Single Sided Deafness and/or Conductive Hearing Loss N/A
Completed NCT03746548 - Audiological Benefit and Quality of Life With Two Bone Conduction Systems: ADHEAR vs. Contact Mini N/A